August 11, 2026

Ref: NEPHROPLUS/SE/69

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai – 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Sub: Outcome of the Board Meeting held on August 11, 2026
Ref: Regulation 30, 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30, 33 and other applicable Regulations, if any, of SEBI Listing Regulations, we hereby inform that the Board of Directors of the Company at its meeting held today, i.e., Tuesday, August 11, 2026, inter-alia, considered and approved:

a. Un-audited Standalone and Consolidated financial results of the Company for the quarter ended June 30, 2026. The said financial results, along with the Limited Review Report issued by M/s. B S R and Co, Chartered Accountants (FRN - 128510W), Statutory Auditors of the Company are enclosed herewith.

b. Reconstitution of the Audit Committee of the Board of Directors of the Company with effect from August 17, 2026. The revised composition of the Audit Committee is as follows:

    a. Mr. Hemant Sultania, Chairman & Independent Director
    b. Ms. Annette Kumlien, Independent Director
    c. Mr. Gaurav Sharma, Nominee Director

c. Reconstitution of the Stakeholders Relationship Committee of the Board of Directors of the Company with effect from August 17, 2026. The revised composition of the Stakeholders Relationship Committee is as follows:

    a. Mr. Vishal Vijay Gupta, Chairman & Nominee Director
    b. Mr. Vikram Vuppala, Managing Director
    c. Mr. Om Prakash Manchanda, Independent Director

Nephrocare Health Services Limited (Global Corporate Headquarters)
(Formerly Nephrocare Health Services Private Limited)
5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500 081, Telangana, India.
+91 40 4240 8039 contactus@nephroplus.com www.nephroplus.com
CIN: L85100TG2009PLC066359 | GSTIN: 36AADCN1504A1Z8 | ISD GST: 36AADCN1504A2Z7

d. The proposed transfer of the 51% shareholding held by Nephrocare Health Services International Pte. Ltd., Singapore ("**NHSI**"), an overseas wholly owned subsidiary of the Company, in Nephrocare Health Services Saudi Arabia Company ("**NHSSAC**"), to NephroPlus Kidney Services Company ("**NPKSC**"), an overseas step-down wholly owned subsidiary of the Company and a wholly owned subsidiary of NHSI, as part of an internal restructuring of the Group's overseas holding structure. Since NPKSC is a wholly owned subsidiary of NHSI, which in turn is a wholly owned subsidiary of the Company, the proposed transfer will not result in any change in the ultimate beneficial ownership or control of NHSSAC.

   The relevant details in respect of the aforesaid internal restructuring, to the extent applicable, as required under the SEBI Listing Regulations read with SEBI Master Circular Ref. No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure I**.

The meeting of Board of Directors commenced at 03:45 p.m. IST and concluded at about 05:10 p.m. IST.

A copy of this disclosure is also made available on the website of the Company www.nephroplus.com

Yours faithfully,
For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)

Kathri Kishore Digitally signed by Kathri Kishore Date: 2026.08.11 17:40:45 +05'30'

Kishore Kathri
Company Secretary and Head Legal
Membership No.: F9895

Annexure I

Sr. No.	Particulars	Details of the Transaction
1.	Name of the target entity, details in brief such as size, turnover etc.	Nephrocare Health Services Saudi Arabia Company **("NHSSAC")**, a company incorporated in the Kingdom of Saudi Arabia and engaged in the business of providing dialysis services. Turnover: NIL for the financial year ended March 31, 2026.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The proposed transaction is an intra-group transaction between related parties. NHSI, the transferor, is an overseas wholly-owned subsidiary of the Company. NPKSC, the transferee, is an overseas wholly-owned of NHSI and consequently an overseas step-down wholly-owned subsidiary of the Company. The Promoter/Promoter Group of the Company does not have any interest in the proposed transaction, except to the extent of their shareholding in the Company. The transaction is being undertaken as part of an internal restructuring of the Group's overseas holding structure and the consideration shall be determined in accordance with applicable valuation and regulatory requirements.
3.	Industry to which the entity being acquired belongs;	Healthcare services - dialysis services.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed transaction is being undertaken as part of an internal restructuring of the Group's overseas holding structure, with a view to streamlining and optimising the ownership structure of the Group's operations in the Kingdom of Saudi Arabia and strengthening governance, operational oversight and strategic alignment. The business of NHSSAC is in line with the principal business activities of the Company and the Group. As NPKSC is an overseas wholly-owned subsidiary of NHSI, which in turn is an overseas wholly-owned subsidiary of the Company, the proposed transaction will not result in any change in the ultimate beneficial ownership or control of NHSSAC.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	The proposed transaction is subject to receipt of the requisite governmental and/or regulatory approvals and compliance with the applicable laws and regulations in the relevant jurisdictions, including Singapore and the Kingdom of Saudi Arabia, as may be applicable.

6.	Indicative time period for completion of the acquisition	The proposed transaction is expected to be completed upon receipt of the requisite approvals and completion of the applicable legal, regulatory and other formalities.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration.
8.	Cost of acquisition and/or the price at which the shares are acquired	The total consideration for the proposed transfer of the 51% shareholding in NHSSAC shall be Saudi Riyal 2.24 million.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	NHSI proposes to transfer its entire 51% shareholding in NHSSAC to NPKSC. Upon completion of the proposed transaction, NPKSC will hold 51% of the shareholding in NHSSAC. The transaction will not result in any change in the ultimate beneficial ownership or control of NHSSAC at the Company/Group level.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	NHSSAC is incorporated in the Kingdom of Saudi Arabia and is engaged in the business of providing dialysis services. Date of incorporation: January 04, 2023. Turnover: • FY26 - Nil • FY25 - Nil • FY24 - Nil Country of presence: Kingdom of Saudi Arabia. NHSI presently holds 51% of the shareholding in NHSSAC, with the remaining 49% held by the local joint venture partner. Pursuant to the proposed internal restructuring, NHSI's entire 51% shareholding is proposed to be transferred to NPKSC.

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited standalone financial results of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited)

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

   Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2025, as reported in the Statement have been approved by the Company's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

AMIT KUMAR BAJAJ

Digitally signed by AMIT KUMAR BAJAJ
Date: 2026.08.11 17:32:22 +05'30'

Amit Kumar Bajaj

Partner

Membership No.: 218685

UDIN:26218685GLQAJD1208

Hyderabad

11 August 2026

Nephrocare Health Services Limited
(formerly Nephrocare Health Services Private Limited)
CIN: L85100TG2009PLC066359
Regd.Office: 5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500081
Email id: cs@nephroplus.com Ph. No. +91 40 4240 8039

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2026

(₹ in Millions, except per share data)

Particulars	Quarter Ended			Year ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	Unaudited	Audited (Refer Note 3)	Unaudited (Refer Note 4)	Audited
Income				
Revenue from operations	1,703.78	1,643.33	1,488.26	6,297.43
Other income	61.24	61.35	29.72	154.34
Total income	**1,765.02**	**1,704.68**	**1,517.98**	**6,451.77**
Expenses				
Cost of materials consumed	421.76	410.12	402.07	1,607.32
Employee benefits expense	308.02	321.55	292.62	1,210.86
Finance costs	4.85	12.72	34.78	497.61
Depreciation, amortisation and impairment expense	130.88	159.48	123.46	576.09
Healthcare professional fees	221.72	208.77	180.82	826.53
Hospital fees	179.00	179.06	163.97	685.33
Other expenses	331.86	303.05	251.28	1,085.72
Total expenses	**1,598.09**	**1,594.75**	**1,449.00**	**6,489.46**
Profit / (loss) before tax	**166.93**	**109.93**	**68.98**	**(37.69)**
Tax expense				
Current tax	60.71	39.06	26.67	141.20
Deferred tax benefit	(19.41)	(38.01)	(7.83)	(98.29)
Total tax expense	**41.30**	**1.05**	**18.84**	**42.91**
Profit / (loss) for the period/year	**125.63**	**108.88**	**50.14**	**(80.60)**
Other comprehensive income				
Items that will not be reclassified to profit or loss				
- Remeasurement gains on defined benefit plans	0.17	1.09	0.66	0.68
- Income tax relating to items above	(0.04)	(0.27)	(0.02)	(0.17)
Total other comprehensive income	**0.13**	**0.82**	**0.64**	**0.51**
Total comprehensive income/(loss)	**125.76**	**109.70**	**50.78**	**(80.09)**
Paid up share capital	200.68	200.68	36.18	200.68
Other equity				9,508.38
Earnings per equity share (₹)*				
Basic earnings per share [In absolute ₹ terms]	1.25	1.09	0.60	(0.89)
Diluted earnings per share [In absolute ₹ terms]	1.22	1.06	0.57	(0.89)

*Earnings per equity share is not annualised for the quarters.

Nephrocare Health Services Limited
(formerly Nephrocare Health Services Private Limited)
CIN: L85100TG2009PLC066359
Regd.Office: 5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500081
Email id: cs@nephroplus.com Ph. No. +91 40 4240 8039

Notes :

1. The above standalone financial results of Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) ("the Company") for the quarter ended 30 June 2026, have been prepared in accordance with the Indian Accounting Standard (referred to as 'Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. These standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 August 2026. The Statutory auditors of the Company have conducted a 'Limited Review' of the standalone financial results and have issued an unmodified review conclusion thereon.

3. The standalone figures for the quarter ended 31 March 2026 are the balancing figures between audited standalone figures for the year ended 31 March 2026 and the published unaudited year to date figures for the nine months ended 31 December 2025.

4. The Company was listed on the stock exchanges on 17 December 2025. Accordingly, the standalone financial results for the corresponding quarter ended 30 June 2025 were not required to be submitted to the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and were consequently not subjected to audit or limited review by the statutory auditors. The comparative figures for the quarter ended 30 June 2025 as included in these standalone financial results, have been approved by the Board of Directors of the Company at its meeting held on 11 August 2026.

5. In accordance with Ind AS 108, Operating segments, segment information has been provided in the consolidated financial results of the Company and no separate disclosure on segment information is given in these standalone financial results.

6. During the year ended 31 March 2026, the Company has completed an initial public offering (IPO) of 18,943,020 equity shares with a face value of INR 2 each at an issue price of INR 460 per share, comprising fresh issue of 7,689,918 shares and an offer for sale of 11,253,102 shares. The Company's equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 17 December 2025.

The utilisation of net IPO proceeds is summarised below:

Objectives	Amount to be utilised as per prospectus	Utilisation up to 30 June 2026	Unutilised as on 30 June 2026
Capital expenditure for opening new dialysis clinics in India	1,291.06	127.68	1,163.38
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed	1,359.99	1,359.99	-
General corporate purposes	600.48	587.16	13.32
Total	**3,251.53**	**2,074.83**	**1,176.70**

7. During the quarter ended 30 June 2026, the Company received share application money amounting to INR 11.28 million pursuant to the exercise of employee stock options under its ESOP Scheme. Subsequently, on 14 July 2026, the Company allotted 144,320 equity shares against such exercises.

8. The standalone financial results for the quarter ended 30 June 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: nseindia.com) and on the Company's website (URL: https://nephroplus.com/investors).

For and on behalf of the Board of Directors of
Nephrocare Health Services Limited
(formerly Nephrocare Health Services Private Limited)

VUPPALA Vikram
Digitally signed by VUPPALA Vikram
Date: 2026.08.11 17:11:20 +05'30'

Vikram Vuppala
Chairman and Managing Director
DIN: 02847323

Place : Hyderabad
Date : 11 August 2026

B S R and Co
Chartered Accountants

Salarpuria Knowledge City, Orwell
B Wing, 6th Floor, Unit-3, Sy No. 83/1
Plot No. 02, Raidurg
Hyderabad – 500 081, India
Telephone + 91 407 182 2000
Fax + 91 407 182 2399

Limited Review Report on unaudited consolidated financial results of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net loss after tax and total comprehensive loss of its joint venture for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

   Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2025, as reported in the Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I.

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Limited Review Report *(Continued)*

Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited)

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

AMIT KUMAR BAJAJ

Digitally signed by AMIT KUMAR BAJAJ
Date: 2026.08.11 17:33:54 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad
Membership No.: 218685

11 August 2026
UDIN:26218685AJFXLH2124

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited)	Holding company
2	Nephrocare Health Services Central Asia FE LLC	Subsidiary
3	Nephrocare Health Services Nepal Private Limited	Subsidiary
4	Nephrocare Health Services International Pte Limited	Subsidiary
5	Nephrocare Health Services Saudi Arabia Company	Joint Venture
6	Nephro Plus Kidney Services Company	Step down subsidiary
7	Nephrocare Health Care Services, Philippines Inc.	Step down subsidiary
8	Anram Medical Group Inc.	Step down subsidiary
9	Bioregen Hemo Center Inc	Step down subsidiary
10	Curis Cavite Renal Corporation	Step down subsidiary
11	Cadiz Dialysis Hub Inc.	Step down subsidiary
12	Curis Hemodialysis Clinic Inc.	Step down subsidiary
13	Carmona Dialysis System Inc.	Step down subsidiary
14	Dialysis Asia and Patient Care Center Inc.	Step down subsidiary
15	Mega Health Dialysis Center	Step down subsidiary
16	Medical Experts Group and Associates Inc	Step down subsidiary
17	People's Center For Hemodialysis Care Inc.	Step down subsidiary
18	Renal Therapy Solutions Inc.	Step down subsidiary
19	Rizal Dialysis and Wellness Centre OPC	Step down subsidiary

20	St. Margareth Dialysis and Biocare Center Inc.	Step down subsidiary
21	Universe Dialysis and Kidney Care Center Inc.	Step down subsidiary
22	AIZ Hemo Dialysis Centre Inc.	Step down subsidiary
23	Infini Care Health Systems Inc.	Step down subsidiary
24	Kolff Dialysis Inc.	Step down subsidiary
25	Nephro Alliance Ventures Inc.	Step down subsidiary
26	Nephroplus Health Services Kazakhstan LLP	Step down subsidiary

Nephrocare Health Services Limited
(formerly Nephrocare Health Services Private Limited)
CIN: L85100TG2009PLC066359
Regd.Office: 5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500081
Email id: cs@nephroplus.com Ph. No. +91 40 4240 8039

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026

(₹ in Millions, except per share data)

Particulars	Quarter ended			Year ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
	Unaudited	Audited (Refer Note 3)	Unaudited (Refer Note 4)	Audited
Income				
Revenue from operations	2,817.54	2,656.15	2,277.83	9,988.45
Other income	74.59	115.69	65.76	245.13
Total income	**2,892.13**	**2,771.84**	**2,343.59**	**10,233.58**
Expenses				
Cost of materials consumed	624.41	596.30	544.68	2,267.89
Employee benefits expense	478.25	459.28	397.96	1,717.89
Finance costs	22.06	31.80	61.04	602.42
Depreciation, amortisation and impairment expense	245.40	258.45	195.20	906.67
Healthcare professional fees	306.14	292.97	243.01	1,121.59
Hospital fees	215.87	212.30	187.13	799.85
Other expenses	554.04	557.62	429.38	1,811.60
Total expenses	**2,446.17**	**2,408.72**	**2,058.40**	**9,227.91**
Profit before share of loss of joint venture and tax	**445.96**	**363.12**	**285.19**	**1,005.67**
Share of loss of joint venture, net of tax	**(35.66)**	**(30.93)**	**-**	**(30.93)**
Profit before tax	**410.30**	**332.19**	**285.19**	**974.74**
Tax expense				
Current tax	120.89	87.81	70.54	355.60
Deferred tax benefit	(30.33)	(59.32)	(22.39)	(149.26)
Total tax expense	**90.56**	**28.49**	**48.15**	**206.34**
Profit for the period/year	**319.74**	**303.70**	**237.04**	**768.40**
Other comprehensive income				
Items that will not be reclassified to profit or loss				
- Remeasurement gains on defined benefit plans	0.16	1.08	0.66	0.67
- Income tax relating to above items	(0.04)	(0.27)	(0.02)	(0.17)
Items that will be reclassified to profit or loss				
- Exchange differences on translating financial statements of foreign operations	10.66	58.46	26.79	185.84
Total other comprehensive income for the period/year	**10.78**	**59.27**	**27.43**	**186.34**
Total comprehensive income for the period/year	**330.52**	**362.97**	**264.47**	**954.74**
Profit attributable to				
Owners of the Company	319.74	303.70	237.04	768.40
Other comprehensive income attributable to				
Owners of the Company	10.78	59.27	27.43	186.34
Total comprehensive income attributable to				
Owners of the Company	330.52	362.97	264.47	954.74
Paid up share capital	200.68	200.68	36.18	200.68
Other equity				10,964.25
Earnings per equity share (₹)*				
Basic earnings per share [in absolute ₹ terms]	3.19	3.03	2.82	8.48
Diluted earnings per share [in absolute ₹ terms]	3.11	2.96	2.70	8.10

*Earnings per equity share is not annualised for the quarters.

Nephrocare Health Services Limited
(formerly Nephrocare Health Services Private Limited)
CIN: L85100TG2009PLC066359
Regd.Office: 5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500081
Email id: cs@nephroplus.com Ph. No. +91 40 4240 8039

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026

Notes :

1. The above consolidated financial results of Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") and its joint venture for the quarter ended 30 June 2026, have been prepared in accordance with the Indian Accounting Standard (referred to as 'Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and in terms of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. These consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 August 2026. The Statutory auditors of the Company have conducted a 'Limited Review' of the consolidated financial results and have issued an unmodified review conclusion thereon.

3. The consolidated figures for the quarter ended 31 March 2026 are the balancing figures between audited consolidated figures for the year ended 31 March 2026 and the published unaudited year to date figures for the nine months ended 31 December 2025.

4. The Company was listed on the stock exchanges on 17 December 2025. Accordingly, the consolidated financial results for the corresponding quarter ended 30 June 2025 were not required to be submitted to the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and were consequently not subjected to audit or limited review by the statutory auditors. The comparative figures for the quarter ended 30 June 2025 as included in these consolidated financial results, have been approved by the Board of Directors of the Company at its meeting held on 11 August 2026.

5. The Statement of unaudited consolidated financial results include the results of the following entities:

a) Parent:

1) Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited)

b) Subsidiaries (including step-down subsidiaries):

1) Nephrocare Health Services Central Asia FE LLC
2) Nephrocare Health Services Nepal Private Limited
3) Nehrocare Health Services International Pte Ltd
4) Nephro Plus Kidney Services Company
5) Nephrocare Health Care Services, Philippines Inc.
6) Anram Medical Group Inc.
7) Cadiz Dialysis Hub Inc.
8) Dialysis Asia and Patient Care Center Inc.
9) People’s Center For Hemodialysis Care Inc.
10) Curis Hemodialysis Clinic Inc.
11) Mega Health Dialysis Center Inc.
12) Universe Dialysis and Kidney Care Centre Inc.
13) St. Margareth Dialysis and Biocare Centre Inc.
14) Medical Experts Group and Associates Inc.
15) Curis Cavite Renal Corporation
16) Renal Therapy Solutions, Inc.
17) Rizal Dialysis and Wellness Centre OPC
18) Bioregen Hemo Center Inc.
19) Carmona Dialysis System Inc.
20) Infini Care Health Systems Inc.
21) Kolff Dialysis Inc.
22) AIZ Hemodialysis Centre Inc.
23) Nephro Alliance Ventures Inc.
24) Nephroplus Health Services Kazakhstan Limited Liability Partnership (LLP) (w.e.f. 26 May 2026)

c) Joint Venture

1) Nephrocare Health Services Saudi Arabia Company

6. The Group's Chief Operating Decision Maker ("CODM"), being the Chairman and Managing Director, reviews the financial performance and allocates resources at the Group level. The Group is principally engaged in providing dialysis services and sale of related healthcare products. Accordingly, the Group has identified a single reportable segment in accordance with Ind AS 108, Operating Segments. Geographical information is disclosed below based on the location of operations as required under Ind AS 108.

Geographical information

Particulars	Quarter ended			Year ended
	30 June 2026	31 March 2026	30 June 2025	31 March 2026
Revenue from operations				
India	1,553.79	1,491.96	1,392.25	5,813.21
Philippines	906.29	846.75	669.37	3,112.28
Uzbekistan	321.34	287.02	216.21	1,004.22
Others	36.12	30.42	-	58.74
Total	**2,817.54**	**2,656.15**	**2,277.83**	**9,988.45**

Nephrocare Health Services Limited
(formerly Nephrocare Health Services Private Limited)
CIN: L85100TG2009PLC066359
Regd.Office: 5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500081
Email id: cs@nephroplus.com Ph. No. +91 40 4240 8039

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026

7. During the year ended 31 March 2026, the Company has completed an initial public offering (IPO) of 18,943,020 equity shares with a face value of INR 2 each at an issue price of INR 460 per share, comprising fresh issue of 7,689,918 shares and an offer for sale of 11,253,102 shares. The Company's equity shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 17 December 2025.

The utilisation of net IPO proceeds is summarised below:

Objectives	Amount to be utilised as per prospectus	Utilisation up to 30 June 2026	Unutilised as on 30 June 2026
Capital expenditure for opening new dialysis clinics in India	1,291.06	127.68	1,163.38
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed	1,359.99	1,359.99	-
General corporate purposes	600.48	587.16	13.32
Total	**3,251.53**	**2,074.83**	**1,176.70**

8. During the quarter ended 30 June 2026, the Group entered into seven asset transfer arrangements for an aggregate consideration of INR 709.30 million. The initial accounting for these business combinations is provisional as the identification and measurement of the assets acquired are yet to be completed. Accordingly, the purchase consideration has been allocated on a provisional basis to tangible assets, intangible assets and goodwill based on management's current assessment. The Group will finalise the initial accounting within the measurement period of up to twelve months from the respective acquisition dates in accordance with Ind AS 103, Business Combinations.

9. On 26 May 2026, the Group incorporated NephroPlus Health Services Kazakhstan Limited Liability Partnership, a wholly owned subsidiary in the Republic of Kazakhstan, to expand its dialysis and related healthcare services operations in Central Asia.

10. During the quarter ended 30 June 2026, the Company received share application money amounting to INR 11.28 million pursuant to the exercise of employee stock options under its ESOP Scheme. Subsequently, on 14 July 2026, the Company allotted 144,320 equity shares against such exercises.

11. The consolidated financial results for quarter ended 30 June 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: nseindia.com) and on the Company's website (URL: https://nephroplus.com/investors).

For and on behalf of the Board of Directors of
Nephrocare Health Services Limited
(formerly Nephrocare Health Services Private Limited)

VUPPALA Vikram
Digitally signed by VUPPALA Vikram
Date: 2026.08.11 17:11:54 +05'30'

Vikram Vuppala
Chairman and Managing Director
DIN: 02847323

Place : Hyderabad
Date : 11 August 2026